| Price Range 12mo avg: | $2M – $2.5M |
|---|---|
| $/sf 12mo avg: | $318.75 |
| CAP Rate 12mo avg: | 7.29% |
| NOI average: | $173,700 |
| Lease Terms: | 15yrs NNN |
| Building Size avg: | 7,500 SF |
| Lot Size avg: | 2.5+/- acres |
Fresenius is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home.
The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS)
Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.7 million individuals worldwide. Through its network of 3,361 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,312 patients around the globe. Fresenius Medical Care is also the world’s leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
| S&P Credit Rating: | BBB- |
|---|---|
| Moody’s Credit Rating: | Ba1 |
| Annual Revenue 2014: | $15.8B |
| Annual Revenue 2013: | $14.6B |
| Revenue Growth: | ↑ 8% from 2013 |
| Net Income | $1.05B |
| Units (Dec. 2014) | 3,361 |
| Average Units Volume: | $4.7M |
Yahoo! Finance: FMS News Latest Financial News for FMS
-
Frenova Renal Research Announces Expansion of F1RST Up™ (Frenova Rapid STart Up) Alliance of Investigative Sites Designed to Speed Clinical Trial Initiation
on June 20, 2017 at 1:30 pm
Frenova Renal Research, the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research, today announced that its F1RST Up™ alliance of clinical research sites focusing on kidney disease has expanded to include 55 physician investigators representing 23 sites. […]
-
ETFs with exposure to Fresenius Medical Care AG & Co. KGaA : June 9, 2017
on June 9, 2017 at 5:32 pm
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Fresenius Medical Care AG & Co. KGaA Here are 5 ETFs with the largest exposure to FMS-US. Comparing the performance and risk of Fresenius Medical Care AG & Co. KGaA with the ETFs that have exposure to it gives us some ETF choices that could ... Read more (Read more...) […]
-
ETFs with exposure to Fresenius Medical Care AG & Co. KGaA : May 19, 2017
on May 19, 2017 at 5:54 pm
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Fresenius Medical Care AG & Co. KGaA Here are 5 ETFs with the largest exposure to FMS-US. Comparing the performance and risk of Fresenius Medical Care AG & Co. KGaA with the ETFs that have exposure to it gives us some ETF choices that could ... Read more (Read more...) […]
-
Fresenius Medical Care AG & Co. KGaA :FMS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017
on May 18, 2017 at 1:49 pm
Categories: Yahoo FinanceGet free summary analysis Fresenius Medical Care AG & Co. KGaA reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Fresenius Medical Care AG & Co. KGaA – DaVita Inc., Baxter International Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Amgen Inc., NxStage ... Read more (Read more...) […]
-
John Oliver ripped into a CEO who proudly compared his healthcare business to Taco Bell
on May 15, 2017 at 3:28 pm
For all the problems with US healthcare, there’s one service that’s been fully funded by the government since 1972. During his troubled tenure as president, Richard Nixon signed a bill into law that provided access to dialysis—a process which externally filters the blood when kidneys fail to do so—to anyone who needs it. As of… […]
NYSE: FMS
